- Trial phase
- Approved
- Time to market
- Already approved and commercially available since September 2024.
- Why 4/10
- Tecentriq Hybreza is already approved and commercially available with no pending PDUFA or pivotal readout in the next ~12 months. For Halozyme, it is one of several ENHANZE royalty-generating products. Label expansions occur periodically but are not binary catalysts for HALO. Per the rubric, an approved, marketed drug with no imminent new regulatory decision scores 3-5.
Tecentriq Hybreza is already approved and generating royalties for Halozyme. Watch for future label expansions by Roche/Genentech that could incrementally boost royalty revenue, and for Halozyme's quarterly royalty reports to track commercial uptake. The next catalyst for HALO as a whole is more likely to be partnership deals, patent litigation outcomes (e.g., the Merck Keytruda Qlex dispute), or quarterly earnings rather than a specific Tecentriq Hybreza event.
Price Chart
Executive Summary
Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) is a subcutaneous formulation of Roche/Genentech's PD-L1 inhibitor Tecentriq, enabled by Halozyme's ENHANZE drug delivery technology. The FDA approved it in September 2024 as the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy, covering all adult indications of IV Tecentriq. Since launch, it has gained additional label expansions including adjuvant bladder cancer (May 2026) and stage III colon cancer (October 2026). For Halozyme (HALO), Tecentriq Hybreza is one of several ENHANZE-partnered products contributing to a rapidly growing royalty stream. Halozyme reported Q3 2026 royalty revenue of $341M (up 44% YoY) and raised full-year guidance. The drug is already approved and commercialized with no upcoming binary catalyst for Halozyme, making it a steady royalty contributor rather than a swing-factor event.
How It Works
Tecentriq Hybreza combines two components: atezolizumab, an immunotherapy antibody that blocks the PD-L1 protein on cancer cells to help the immune system attack them, and hyaluronidase, an enzyme that temporarily breaks down a gel-like substance under the skin (hyaluronic acid) so the large antibody volume can be absorbed. This allows a quick subcutaneous injection (about 7 minutes) instead of a 30-60 minute intravenous infusion. The hyaluronidase component is Halozyme's ENHANZE technology.
Trial Status
Tecentriq Hybreza received FDA approval on September 13, 2024 for all adult indications of IV Tecentriq, based on data from the Phase 3 IMscin001 trial and pharmacokinetic bridging studies showing comparable efficacy and safety to IV administration. Since then, the FDA has approved multiple label expansions alongside the IV formulation: adjuvant muscle-invasive bladder cancer with ctDNA guidance (May 2026), first-line maintenance for extensive-stage small cell lung cancer with lurbinectedin (October 2025), and adjuvant stage III dMMR colon cancer with chemotherapy (October 2026).
The Two-Sided Case
Upcoming Catalysts
- No specific upcoming binary catalyst for Tecentriq Hybreza identified. Future label expansions by Roche/Genentech could incrementally boost Halozyme's royalty revenue, but these are not scheduled binary events for HALO.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
HALOZYME THERAPEUTICS, INC. 8-K HALO ·Originating report